Zorick, Todd S.; Mustacchi, Zan; Bando, Sílvia Yumi; Zatz, Mayana 
; Moreira-Filho, Carlos Alberto; Olsen, Björn; Passos-Bueno, Maria Rita
Fonte: European Journal of Human Genetics. Unidade: IB
Assunto: SÍNDROME DE DOWN
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZORICK, Todd S. et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics, v. 9, p. 811-814, 2001Tradução . . Disponível em: https://doi.org/10.1038/sj.ejhg.5200721. Acesso em: 18 set. 2024.APA
Zorick, T. S., Mustacchi, Z., Bando, S. Y., Zatz, M., Moreira-Filho, C. A., Olsen, B., & Passos-Bueno, M. R. (2001). High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics, 9, 811-814. doi:10.1038/sj.ejhg.5200721NLM
Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours [Internet]. European Journal of Human Genetics. 2001 ; 9 811-814.[citado 2024 set. 18 ] Available from: https://doi.org/10.1038/sj.ejhg.5200721Vancouver
Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours [Internet]. European Journal of Human Genetics. 2001 ; 9 811-814.[citado 2024 set. 18 ] Available from: https://doi.org/10.1038/sj.ejhg.5200721
